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RETINAL VASCULAR BLOOD FLOW 
IN PATIENTS WITH RETINAL VEIN OCCLUSIONS 
RACHELLE ELIF KOCH 
ABSTRACT 
Purpose: This study aims to quantify the retinal vascular blood flow in eyes 
affected by unilateral central retinal vein occlusions (CRVO) or branch retinal 
vein occlusions (BRVO). We created and explored a new, unitless metric for the 
severity of these diseases: relative blood flow (RBF). We then contextualized 
RBF in terms of patient demographics, ocular presentation and other systemic 
conditions, as well as explored its efficacy as a predictor of future outcomes. 
Methods: Data was collected from 20 control subjects and 32 patients with 
clinically diagnosed retinal vein occlusions (15 CRVO and 17 BRVO). Laser 
speckle flowgraphy was then used to quantify retinal vascular blood flow in terms 
of mean blur rate, a metric shown to be highly heterogeneous between patients 
but fairly consistent in intra-patient repeated measurements over time. After 
confirming this and establishing a strong correlation between a healthy patient’s 
two eyes, we used an RVO patient’s fellow eye as a nondiseased expectation 
and presented relative blood flow as the ratio between their diseased and healthy 
eye. We then correlated this data with demographic variables and disease 
characteristics from patients’ medical history. 
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Results: We found an average blood flow decrease of 26% in CRVO eyes 
relative to healthy eyes in the same patients and an average decrease of 7% in 
BRVO eyes. In CRVO, duration of occlusion, central macular thickness, 
intraocular pressure, diabetes, previous laser and injection treatments, and an 
injection within three months after blood flow measurement were significantly 
associated with relative blood flow. In BRVO, no demographic variables or 
disease characteristics were significantly associated with relative blood flow. 
Conclusions: Relative blood flow represents a promising new, consistent and 
informative metric for quantifying the severity of unilateral retinal vein occlusions. 
With both descriptive and predictive properties in eyes with CRVO, future work 
should explore its great potential.  
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INTRODUCTION 
The eyes are required for the sensory modality of vision and play an 
important role in interpersonal interaction and communication. Diseases of the 
eye can therefore have a profound effect on quality of life. Vision can be impaired 
by any condition decreasing or preventing the passage of light toward the back of 
the eye or impairing the conversion of light into neural signals for processing by 
the brain. The structure of the eye is fundamental to its function (Batterbury & 
Murphy, 2019).  
Anatomy of the Eye 
The tissue architecture of the eye serves to transmit and focus light 
(Figure 1). Two structures, the cornea and conjunctiva, are in direct contact with 
the environment and protect the eye from mechanical or chemical trauma. The 
cornea is transparent because of its molecular architecture: there are no blood 
vessels, thin-diameter collagen is laid out in a highly regular fashion, and water is 
actively transported out of the tissue (Meek & Knupp, 2015). The anterior 
chamber, iris, pupil, and posterior chamber lie behind the cornea, and these 
components are in contact with the aqueous fluid. The lens separates the 
aqueous fluid from the vitreous, which contains a gel-like fluid that occupies a 
majority of the eye. Light travels through these elements to arrive at its final 
destination located in the posterior aspect of the eye, the retina (Kolb, 2007). 
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Figure 1. Gross anatomy of the eye. This graphic shows a cross-section of the 
eye, with light entering through the anterior aspect of the eye (on the left) where 
the cornea and the lens are located. Light traverses the vitreous and arrives at 
the retina in the posterior pole of the eye (on the right). 
Structure of the Retina 
 Histologically, the retina is comprised of stratified layers of neural, 
connective, epithelial tissue. The neuronal cell layers are responsible for 
conversion of light into neural signals, which are conveyed to the brain via the 
optic nerve. Light must pass through the eight inner, anterior layers of the retina 
before it reaches the photoreceptor rod and cone cells (Figure 2). Electrical 
signals from photoreceptors are transmitted through the signal-conducting bipolar 
and amacrine cells to the ganglion cells. The axons of the ganglion cells travel 
toward the optic disk and eventually enter the optic nerve, bringing the signals to 
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the brain. The ganglion cells and the photoreceptor cells form the inner and outer 
boundaries of the neurosensory retina, respectively (Kolb, 2012). 
 
Figure 2. Schematic of the microscopic structure of the retina. There are ten 
distinct cell layers in the retina, with different populations of cells inhabiting the 
layers. Light enters the retina from the innermost (anterior) layer. In this 
schematic, the ganglion cell axons are traveling to the right toward the optic disk 
and nerve. 
Function of the Retina 
 The retina creates sight. Among the previously mentioned neurosensory 
retina cells, the photoreceptor cells are the most important for vision. Both types 
convert light energy into electrical energy through structural and chemical 
intracellular changes. Photoreceptor rods are responsible for vision and 
recognition of movement in low-light conditions. In contrast, the photoreceptor 
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cones function optimally in a bright environment and generate high-acuity color 
vision (Molday & Moritz, 2015). 
 The anatomical location of the photoreceptors impacts vision. Rods are 
located throughout the retina except in the foveola, while cones are localized to 
the macula and particularly concentrated in the fovea and foveola. The macula 
supports central vision, and the rest of the retina provides for peripheral vision. 
The optic disk, an entry and exit point for blood vessels and the optic nerve, is 
devoid of photoreceptors and therefore constitutes a physiological blind spot 
(Figure 3) (Purves et al., 2001). 
 
Figure 3. Fundus schematic of the left eye. The four main tributaries of the 
central retinal artery and vein are shown. In relation to venules, arterioles are 
generally smaller in diameter and have a lighter red color. The arterioles 
eventually branch into capillaries which coalesce back into venules (capillaries 
not shown). The optic disk is the area where the optic nerve and the central 
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retinal vessels enter and exit. The right eye fundus is an approximate mirror 
image of this schematic. 
 Histological examination reveals that the photoreceptor cells are anchored 
to retinal pigment epithelium (RPE) cells, which provide nutrients and 
phagocytose light-damaged cells. Because the photoreceptors comprise the 
outermost layer of the neurosensory retina, any loss of retinal transparency in the 
inner layers, due to a breach of the blood-retinal barrier, for example, can 
negatively affect vision. Photoreceptor cell physiology may also be impacted by a 
breakdown in the connection between the photoreceptor layer and the RPE. 
Provided the anterior elements of the eye transmit and focus light normally, 
proper functioning of the retina is paramount for good vision (Ivanova et al., 
2019). 
Retinal Vasculature 
 The retina receives blood from two sources derived from the ophthalmic 
artery. The network of capillaries within the choroid, or choriocapillaris, supplies 
the posterior, outer third of retinal layers and the foveola entirely. Choroidal 
vessels are bounded by fenestrated epithelium, so the RPE forms the outer 
blood-retinal barrier. The central retinal artery provides oxygen and nutrients to 
the anterior, inner two-thirds of the retina, from the nerve fiber layer to the outer 
plexiform layer. Despite its name, the central retinal artery is an arteriole which 
enters the eye from the optic nerve and branches into a capillary network that 
eventually coalesces into the central retinal vein. The central retinal vein exits the 
eye adjacent to the central retinal artery. Retinal capillaries are bounded by non-
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fenestrated epithelium with tight junctions, forming the inner blood-retinal barrier. 
The foveola is particularly vulnerable to harm because it relies on the 
choriocapillaris as its sole wellspring of nourishment and damage to this area will 
have a pronounced effect on central vision (Sun & Smith, 2018). 
Retinal Vascular Occlusions 
 Retinal vascular occlusions occur when retinal arteries or veins become 
obstructed by compression or by a blood clot, also known as a thrombus. 
Virchow’s Triad is a set of conditions that increase the probability of thrombosis: 
stasis in blood flow, increase in blood coagulability, and injury to the endothelial 
lining of blood vessels. Systemic disease can also impact that likelihood of a 
retinal vascular occlusion from occurring and differ depending on the type of 
occlusion. There are four main categories of retinal vascular occlusions, 
determined by the vessel type and affected site: central and branch arterial 
occlusions, abbreviated CRAO and BRAO, and central and branch retinal vein 
occlusions, abbreviated CRVO and BRVO (Table 1). Arterial occlusions usually 








Table 1. Types of vascular occlusions in the retina and their causes 
Disease Affected Site Etiology 
Central Retinal Arterial 
Occlusion (CRAO) 
Central retinal artery at or 
near the lamina cribrosa 
- Embolism from carotid or cardiac 
vessel thrombi 
 
- Basement membrane thickening 
caused by atherosclerosis 
Branch Retinal Arterial 
Occlusion (BRAO) Smaller arterioles 
Central Retinal Vein 
Occlusion (CRVO) 
Central retinal vein at or 
near the lamina cribrosa 
- Thrombosis due to 
hypercoagulability states, endothelial 
damage, or stasis of blood flow 
 
- Compression of a venule crossing 
under an arteriole 
Branch Retinal Vein 
Occlusion (BRVO) 
Smaller venules, often at 
arteriovenous intersections 
 
(1) Pathogenesis of Retinal Arterial Occlusions (RAO) 
 Systemic conditions associated with retinal arterial occlusions include 
hypertension, ischemic heart disease, carotid occlusive disease, and diabetes 
mellitus. Hyperlipidemia and atherosclerosis are also associated with RAO 
(Hayreh et al., 2009). When considering Virchow’s Triad in the context of RAO 
pathogenesis, factors that affect vessels from outside the wall, within the wall, 
and in the lumen must be considered. Very high intraocular pressure can 
compress arterioles. Atherosclerosis and arteriosclerosis thicken vessel walls 
and can occlude the lumen. Excess white or red blood cells may decrease blood 
flow rate (Hayreh, 2011). The arterial circulation is vulnerable to embolism, in 
which an object traveling through the blood stream lodges in the lumen of an 
artery or arteriole and blocks it. Emboli are relevant to arterial occlusions 
because the cross-sectional diameter of the vessel lumen on the arterial side of 
circulation decreases progressively. Emboli have varying compositions: they can 
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be calcific, fibrin and platelets, cholesterol, or, in the case of a myxoma, 
connective tissue. In some patients, the emboli may eventually pass through the 
vessel, allowing for resolution of vision loss (Yu et al., 2014; Cho et al., 2016). 
(2) Pathogenesis of Retinal Vein Occlusions (RVO) 
 Due to the lower hydrostatic pressure within veins relative to arteries, the 
elements of Virchow’s Triad that can cause RVO are slightly different from those 
that cause RAO. The systemic conditions associated with RVO relate to clotting 
tendency, where hyperviscosity states lead to higher chance of thrombus 
development. A meta-analysis of thrombophilic risk factors found an association 
between RVO and two conditions: hyperhomocysteinemia and presence of 
anticardiolipin antibodies (Janssen et al., 2005).  
 While CRVOs are due to obstruction at or near the lamina cribrosa, 
BRVOs often occur by compression at arteriovenous crossing points, where an 
arteriole passes anterior to the venule. Because an arteriole and venule can 
share a common adventitial sheath, any thickening of a sclerotic arteriole may 
cause compression of the paired venule (Duker, 1989; O’Mahoney, 2008). This 
leads to upstream venous dilation and turbulence of blood flow in the area. A 
change in the blood flow pattern at these sites can induce the formation of a 
thrombus (Christoffersen & Larsen, 1999). Elevated intraocular pressure (IOP) 
due to pre-existing glaucoma or ocular hypertension, is thought to exacerbate the 
compression of retinal venules and is associated with CRVO (Hayreh et al., 
2004). 
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 Vessel wall inflammation of veins, phlebitis, can also occlude the lumen. 
Phlebitis may arise from systemic conditions such as sarcoidosis, systemic lupus 
erythematosus, polyarteritis nodosa, and Behçet’s disease, but there is little 
evidence showing that RVO is caused by these diseases. An observational case 
series on focal retinal phlebitis in three patients with BRVO could not attribute the 
RVO to a systemic predisposition for inflammation (Hoang et al., 2012). An older 
case series suggests that a physically compromised endothelium may result in 
increased permeability and leakage of fluid into the surrounding tissue (Clemett, 
1974). More research is needed to clarify the role of endothelial inflammation in 
RVO. 
(3) Treatments and Outcomes of Retinal Vascular Occlusions 
 A patient who presents with RAO should be evaluated for associated 
neurologic and cardiovascular conditions, so that treatment not only addresses 
the RAO but also the underlying systemic cause (Biousse et al., 2018). With 
complete CRAO, treatment must be within 12-48 hours after the onset of 
symptoms or permanent vision loss can occur (Pielen et al., 2015). Loss of vision 
is less pronounced with BRAO, as it affects a smaller area of the visual field 
(Yuzurihara & Iijima, 2004).  
 If the arterial blockage is resolved by therapy or spontaneously, it is 
possible to fully regain vision. When CRAO is caused by an embolus, treatments 
work toward dilating the arteries, increasing perfusion pressure, dissolving the 
clot, physically removing the embolus, preventing platelet activation, and 
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reducing blood cell rigidity. One systematic review suggests that administration of 
oral pentoxifylline to make red blood cells more deformable or enhanced external 
counterpulsation to increase retinal perfusion are the most justifiable treatments 
for CRAO. Enhanced external counterpulsation has been applied to BRAO as 
well, though none of the therapies addressing RAO have been reliably proven 
(Fraser & Adams, 2009). 
 Similar to RAO, RVO treatments should take patients’ systemic conditions 
into account. However, most studies support treatments that address the 
symptoms of RVO rather than the underlying causes, because the causal 
connections between many systemic conditions and RVO are tenuous. The 
treatments and outcomes of RVO will be discussed in further detail in following 
sections. 
Clinical Presentation of Retinal Vein Occlusions (RVO) 
 RVO is a relatively common vision-impairing vascular eye disorder (Laouri 
et al., 2011). In 2015, the global prevalence of RVO in people aged 30-89 was 
estimated to be 0.77%, or about 28 million people. The prevalence of CRVO at 
that time was approximately 0.13% or 4.67 million individuals, while the 
prevalence of BRVO was about 0.64% or 23.38 million individuals. The pooled, 
cumulative incidence over the span of five years for both types of RVO was 
0.86% and jumped to 1.63% over ten years. Age and prevalence show the 
strongest positive correlation, suggesting a link between advanced age and 
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RVO. There was no significant difference in prevalence between males and 
females (Song et al., 2019).  
 The first sign of retinal vein occlusion may be sudden, painless vision loss 
in an otherwise asymptomatic eye. RVO may also be diagnosed before vision 
loss occurs upon routine ophthalmic examination of the retina. In acute RVOs, 
fundoscopy reveals retinal hemorrhages and dilated tortuous veins. Retinal 
hemorrhages can be sparse or abundant and vary in shape from punctate to 
flame-shaped (Figure 4). Hemorrhages resolve over time, so they may not be 
present in older occlusions. Cystoid macular edema and optic disk edema may 
be observed in older RVO. The clinical manifestations of proliferative diabetic 
retinopathy (PDR) are similar to RVO; therefore, the patient should be assessed 
for diabetes during evaluation (Wong, 2010). 
 
Figure 4. Fundus photograph of a branch retinal vein occlusion. Panel A: A 
widefield fundus photograph of a patient’s healthy, right eye (OD). Blood vessels 
are clearly visible, and the translucent light red patterning in the background is 
the choroidal vasculature. Note that the patient’s eyelashes appear as shadows 
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at the bottom of the photo. Panel B: A widefield fundus photograph of the same 
patient’s left eye (OS), diagnosed with superior BRVO. Retinal veins appear 
dilated when compared to the right eye. There is minimal tortuosity, perhaps due 
to the milder nature of this particular BRVO. Vascular leakage can be seen 
above the fovea, in the superior quadrant of the macula. Both images were 
obtained with an Optos camera (Optos California, Dunfermline, UK). 
 Among RVO subtypes, CRVO results in the greatest severity of symptoms 
(Figure 5). CRVO affects all quadrants of the fundus (Wong, 2010). Almost 40 
years ago, CRVO was designated as ischemic or nonischemic based primarily 
on the amount of nonperfusion visualized by fluorescein angiography (FA), a 
diagnostic imaging technique to be discussed in greater detail in the next section 
(Hayreh, 1983). Relative afferent pupillary defect is another indicator of ischemic 
CRVO (Servais et al., 1986). Ischemic CRVO reflects a different prognosis from 
nonischemic CRVO. Though macular edema may cause a decrease in visual 
acuity in both types, ocular neovascularization is a consequence of the former 
rather than the latter (Thomas et al., 2019).  
 BRVO results in milder symptoms than CRVO. BRVO affects only one 
quadrant of the fundus (Oztas et al., 2017). The negative effect of BRVO on 
retinal blood flow is attenuated by the presence of collateral vessels, which serve 
as alternate paths for blood flow. This is in contrast to CRVO, because the area 
surrounding the lamina cribrosa does not contain collateral channels to allow for 





Figure 5. Relative symptom severity scale of retinal vein occlusions. 
Fundoscopy reveals a greater area of retinal hemorrhages and dilated, tortuous 
vessels in CRVO relative to BRVO. Patients with CRVO usually present with 
greater vision loss than BRVO patients.  
Diagnostic Imaging Techniques for Retinal Vein Occlusions 
 There are a multitude of diagnostic imaging techniques that 
ophthalmologists can use in the diagnosis of RVO. Fluorescein angiography and 
optical coherence tomography are among the more frequently used. This section 
will provide a brief overview of the benefits and limitations of pertinent imaging 
techniques.  
(1) Fluorescein angiography (FA) 
 Since its development in the 1960s, FA has been invaluable to the 
assessment of retinal circulation (Novotny & Alvis, 1961). A fluorescent dye is 
injected into the arm of the patient, and, within seconds, the dye can be 
visualized in the retina. A fundus camera is used to take photographs at various 
time points following the injection of the dye. Recently, the advent of ultra-
widefield fundus cameras (Optos California, Dunfermline, UK) has allowed for 
imaging of a greater field of view--up to 200 degrees horizontally (Callaway & 
Mruthyunjaya, 2019). FA provides a way of visualizing areas of vascular 
occlusion and leakage (Figure 6). However, it is an invasive procedure and can 
CRVO    BRVO 
more severe less severe 
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be difficult to repeat (Osamura et al., 2017). In some rare cases, the fluorescent 
dye can cause severe side effects (Stein & Parker, 1971). 
 
Figure 6. Fluorescein angiography of a branch retinal vein occlusion. Panel 
A: A widefield FA of a patient’s healthy, right eye (OD). Blood vessels are clearly 
visible due to the presence of FA. Panel B: A widefield FA of the same patient’s 
left eye (OS), diagnosed with superior BRVO. Vascular leakage can be seen 
above the fovea, in the superior quadrant of the macula. Both images were 
obtained with an Optos camera (Optos California, Dunfermline, UK). 
(2) Optical Coherence Tomography (OCT) 
 Spectral domain OCT (Heidelberg Engineering, Inc., Heidelberg, 
Germany), which became available for clinical use in 2005, is an extremely 
versatile, noninvasive imaging technique. It provides a cross-sectional image of 
the posterior aspect of the vitreous, the retina and its various optical layers, the 
choroid, and the sclera (Figure 7). The optical layers of the retina correspond to 
its histological layers. Moreover, OCT allows for the fast identification of macular 
edema, macular hole, epiretinal membrane, retinal detachment, and 
morphological changes in the layers of the retina (Theelen & Teussink, 2018).  
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 In 2012, swept source OCT improved upon spectral domain OCT by 
allowing for greater depth of tissue penetration and faster data acquisition (Kishi, 
2016). Doppler Fourier-domain OCT further extended this technology by allowing 
for retinal blood flow measurement using Doppler shift (Doblhoff-Dier et al., 
2014). OCT angiography (OCTA) is another recent enhancement of OCT that 
reveals ocular blood flow and provides a high-resolution map the retinal 
vasculature. OCTA may be favored over FA because it does not require the 
injection of dye and provides information on all layers of retinal blood vessels. 
There are some drawbacks to OCTA. When compared to FA, OCTA does not 




Figure 7. Spectral domain optical coherence tomography of the fovea. 
Panel A: A 90-degree line scan of the healthy, right eye (OD) of a patient. The 
fovea and various retinal layers are visible, and the retina is attached. There is no 
macular edema or epiretinal membrane. Panel B: A 90-degree line scan of the 
left eye (OS), diagnosed with superior BRVO, of the same patient. On the left 
side of the panel, cystoid macular edema is visible as a diffuse dark area in the 
upper half of the image. On the right side of the panel, in the cross-sectional 
scan, the thickening of the retina and black spots within the retina indicate CME. 
There is no epiretinal membrane. All images were obtained with an SD-OCT 
(Heidelberg Engineering, Inc., Heidelberg, Germany). 
(3) Laser Speckle Flowgraphy (LSFG) 
 Laser Speckle Flowgraphy-NAVI (Softcare Co., Ltd., Fukuoka, Japan), 
approved by the FDA in 2016, is a relatively new, noninvasive technology for 
characterizing blood flow in the macula and optic nerve head. This method was 
first proposed in 1981 and, in the late 1990s, developed into a clinical apparatus, 
consisting of a laser and fundus camera for quantitative blood flow measurement 
(Fercher & Briers, 1981; Tamaki et al., 1997). The diode laser (Power: Laser 
Class 1) emits light at 830 nanometers to illuminate a six millimeter by four 
millimeter area on the retina. Erythrocytes moving through retinal vessels scatter 
this light, and the constructive and destructive interference creates a laser 
speckle pattern that is captured by a camera (Figure 8). The primary output of 
the system is mean blur rate (MBR), a numerical measure of blood flow, in 
arbitrary units. The unitless nature of MBR makes it difficult to compare with 
other techniques. For high quality data, there must be little to no opacity in the 
cornea, lens, and vitreous, and the subject must be able to fixate on a target 




Figure 8. Laser speckle flowgraphy of the macula.The areas of high blood 
flow are red, while areas of low blood flow are blue. Panel A: A composite map of 
the healthy, right eye (OD) of a patient. Panel B: A composite map of the same 
patient’s left eye (OS), which was diagnosed with BRVO in the superior quadrant. 
Panel C: The average mean blur rate (MBR) in the rubber band (RB) encircling 
the optic nerve head in the composite map in Panel A. The composite map is 
comprised 25 heartbeat maps, taken sequentially and overlaid on one another. 
These heartbeat maps are represented as 25 frames on the x-axis of the graph. 
Change in MBR over time is caused by cycling between systole and diastole; 
moreover, each graph represents one heartbeat. Panel D: The average mean 
blur rate (MBR) in the rubber band (RB) encircling the optic nerve head in the 
composite map in Panel B. All images were obtained with the LSFG-NAVI 
system and accompanying software (Softcare Co., Ltd., Fukuoka, Japan). 
(4) Other Technologies 
 Many other technologies have been used to analyze retinal vasculature 
and blood flow (Wei et al., 2018). Some older noninvasive techniques include 
blue-field entoptic simulation and laser doppler velocimetry. Blue-field entoptic 
simulation enlists the patient in tracking the movement of their own leukocytes 
when looking into a blue background, but this technique is limited by bias 
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introduced by patients (Riva & Petrig, 1980). Laser doppler velocimetry 
measures absolute erythrocyte velocity, but it makes multiple idealistic 
assumptions about retinal vessels and blood flow dynamics (Riva et al., 1979). 
Laser doppler flowmetry is a slightly newer technique that is similar in principle to 
LSFG, but the extent to which different layers of microcirculation contribute to the 
signal must be clarified (Riva et al., 2010). The adaptive optics scanning laser 
ophthalmoscope allows for measurement of absolute blood velocity in individual 
blood vessels (Zhong et al., 2011). 
 Ophthalmodynamometry is a diagnostic technique that is not based on 
visualization of the retina. Rather, it is a way of assessing the pressure within the 
central retinal vein and can potentially identify CRVO. However, in order to 
distinguish between the effect of an occlusion and IOP on retinal venous 
pressure, the patient’s fellow eye must be healthy and have a similar IOP (Jonas, 
2004; Robert, 2004). 
Risk Factors for Retinal Vein Occlusions 
 In general, advanced age and vascular or hematological diseases are risk 
factors for retinal vein occlusion. Studies on RVO, therefore, tend to evaluate the 
traditional risk factors for atherosclerosis: hypertension, hyperlipidemia, and 
diabetes (O’Mahoney, 2008). A recent meta-analysis examining epidemiological 
studies of RVO identified age and hypertension as the strongest risk factor for 
the disease. In 2015, the global prevalence of RVO was less than 1% for people 
in their 30s, 40s, and 50s, and greater than 1% for those in their 60s, 70s, and 
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80s. Heart attack and stroke history, high cholesterol, and high creatinine were 
also significantly correlated with RVO. Diabetes mellitus was not a significant risk 
factor (Song et al., 2019). In a 12-year longitudinal study conducted in South 
Korea, researchers found an increased risk of RVO in patients with end-stage 
renal disease, which is associated with cardiovascular and thrombotic disorders 
(K. S. Lee et al., 2018). 
 Some sources suggest that there are etiological differences between 
young and old people who present with CRVO. So-called nontraditional risk 
factors—disorders causing aberrant inflammatory responses, connective tissue 
abnormalities, or hypercoagulability states—are associated with CRVO in people 
under the age of 50 (Rothman et al., 2019). Hypercoagulability and endothelial 
changes may also be a result of oral contraception usage (Stowe et al., 1978). 
Additionally, in patients with CRVO, the sclera and lamina cribrosa of their 
affected eye was significantly thicker than that of sex- and age-matched control 
subjects (Adiyeke et al., 2020).  
 The anatomical distribution of retinal vessels seems to play a role in the 
genesis of BRVO. When the superior and inferior temporal retinal veins were 
closer to the foveal center than both paired temporal retinal arteries, patients 
were less likely to develop BRVO (Oztas et al., 2017).  
Complications of Retinal Vein Occlusions 
 Decreased vision and cystoid macular edema (CME) are the most 
common complications of RVO. CME is swelling of the retina caused by 
 20 
interstitial fluid entering into the tissue due to a breakdown of the outer or inner 
blood-retinal barrier. Using OCT cross-sectional scans of the retina, it is possible 
to measure the central macular thickness (CMT) in micrometers. CMT reflects 
the height of the fovea and is increased where there is fluid buildup (Rotsos & 
Moschos, 2008). Studies examining the correlation of vision loss and increased 
CMT due to macular edema in patients with RVO found no or poor correlations 
between CMT and visual acuity (VA) (Ou et al., 2017; Scott et al., 2009). These 
findings suggest that other factors beyond the amount of macular edema at the 
fovea are driving vision loss. 
 The exact mechanism of vision impairment in people with RVO is unclear, 
though CME is thought to play a major role. Theories for the causes of vision loss 
fall into three main categories: damage of photoreceptor cells, damage of cells in 
the inner retinal layers, and retinal swelling (Iijima, 2018). Blood and lipoproteins 
infiltrating the subretinal space have been shown to cause photoreceptor cell 
death in rabbit and mouse models (Bhisitkul et al., 2008; Notomi et al., 2013; 
Tsujikawa et al., 2010). Apoptosis of cells in the inner nuclear and ganglion cell 
layers was hypothesized to be detrimental to vision because the cells in these 
layers convey signals from the photoreceptors to the optic nerve. However, 
research in this area has been inconclusive (Finkelstein, 1992; Tadayoni et al., 
2016). Finally, macular edema does not affect the transmission of light through 
the outer layers of the retina to the photoreceptor layer. Rather, CME may affect 
neural transduction between bipolar cells and photoreceptors by changing the 
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extracellular matrix composition (Yasuda et al., 2015). While macular edema is 
reversible, deterioration of photoreceptor cells and inner retinal layers may be 
irreversible and responsible for poor visual outcomes even after resolution of 
macular edema. 
 With RVO the formation of an epiretinal membrane and consequent visual 
distortion is sometimes observed. An epiretinal membrane is a clear, contractile 
tissue that forms between the vitreous and the retina and exerts a mechanical 
force, or traction, on the retina. Retinal traction manifests as visual distortion. The 
reason for growth of an epiretinal membrane secondary to BRVO is unknown 
(Kang et al., 2015). 
 Prompt treatment of RVO is necessary to prevent or minimize and delay 
more severe complications. Left untreated, RVO may lead to neovascularization 
of the iris, angle, or the retina, retinal detachment, and, in rare cases, macular 
infarction (Kim et al., 2015; Tsujikawa et al., 2010). Patients with ischemic CRVO 
tend to develop neovascularization of the iris, or rubeosis iridis, and 
neovascularization of the angle which can lead to secondary neovascular 
glaucoma (Boyd et al., 2002; Rong et al., 2019).  
 CRVO often gives rise to dilation of small vessels on the optic veins called 
optociliary shunt vessels connecting the retinal vasculature to the choriocapillaris 
at the optic nerve head (Masuyama et al., 1990). In contrast, neovascularization 
of the retina mainly occurs in patients with severe BRVO (Sakimoto et al., 2020). 
These complications can be debilitating, painful, and require urgent treatment. 
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Treatments for Retinal Vein Occlusions 
 The current standard of care for RVO is generally targeted at relieving 
symptoms rather than addressing an underlying, systemic cause. Treatment can 
differ based on how long a patient has had an occlusion. When patients present 
with acute RVO, they receive a series of intravitreal anti-VEGF injections and 
laser treatments to prevent decreases in visual acuity (VA) and increases in 
macular edema. Additional treatment options include intravitreal corticosteroid 
injections, gas inhalation therapies, surgery, and close observation (Wong, 
2010).  
(1) Injection 
 Two main types of intravitreal injections exist for use in RVO patients: anti-
VEGF and corticosteroids. Retinal tissue hypoxia due to RVO leads to the 
upregulation of vascular endothelial growth factor (VEGF), which promotes 
vascular leakage. Fluid escape from leaking vessels causes cystoid macular 
edema (Aiello et al., 1994; Pe’er & Folberg, 1998). Anti-VEGF injections work by 
preventing breakdown of the blood-retinal barrier. Several studies have 
demonstrated the efficacy of three different anti-VEGF agents: ranibizumab 
(Lucentis), aflibercept (Eylea), and bevacizumab (Avastin). 
 In clinical trials with end points at 6 months, ranibizumab reduced macular 
edema in BRVO and CRVO patients (Brown et al., 2010; Campochiaro et al., 
2010). In two year-long clinical trials, aflibercept reduced macular edema in 
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BRVO and CRVO patients (Clark et al., 2016; Garcia-Arumi et al., 2018). A 
systematic review found that bevacizumab improves VA and reduces CME over 
three months, and statistically significantly improves VA within the first month  
(Yilmaz & Cordero-Coma, 2012). Bevacizumab reduces CME in patients with 
ischemic CRVO but does not improve visual outcomes (Hall et al., 2019). One 
recent clinical trial compared all three intravitreal anti-VEGF agents for reducing 
macular edema in CRVO. At 100 weeks, ranibizumab and aflibercept were 
functionally interchangeable, though the same could not be claimed for 
bevacizumab (Hykin et al., 2019). The optimal dosage schedule for these anti-
VEGF agents for both types of RVO has yet to be established (Lip et al., 2018). 
 Studies aiming to elucidate the molecular mechanisms by which these 
anti-VEGF agents ameliorate retinal vein occlusion are ongoing. One study found 
that bevacizumab increased levels of transthyretin, a tetrameric protein normally 
synthesized by RPE cells in the retina. Transthyretin may somehow prevent 
vascular leakage and development of neovascularization, but more evidence is 
needed to support this hypothesis (Cehofski et al., 2018). 
 Corticosteroids have an inhibitory effect on VEGF and the inflammatory 
response. Triamcinolone acetonide is an injectable corticosteroid that seems to 
improve macular edema over 10-12 months in patients with nonischemic CRVO 
(Bashshur, 2004; Ip et al., 2009). In BRVO, however, triamcinolone is less 
effective than bevacizumab (Higashiyama et al., 2013). Dexamethasone 
(Ozurdex), an intraocular steroid implant, improves VA outcomes in patients with 
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BRVO and CRVO, but has side effects of cataract and increased IOP (Haller et 
al., 2011). Between corticosteroid and anti-VEGF injections, the latter is more 
often used to treat RVO due to is greater efficacy and better risk profile. 
(2) Laser 
 Panretinal laser photocoagulation is thought to prevent development of 
neovascularization, vitreous hemorrhage, and improve visual acuity. According to 
one study, macular edema in patients with CRVO and BRVO did not improve 
with scatter, panretinal laser photocoagulation (Campochiaro et al., 2015). 
However, a recent systematic review found that panretinal laser therapy for 
ischemic CRVO prevents neovascularization of the retina and iris and improves 
macular edema (Li et al., 2018). Scatter photocoagulation was found to prevent 
neovascularization in BRVO (The Branch Vein Occlusion Study Group, 1984). 
Macular grid laser therapy does not, however, appear to improve macular edema 
in patients with BRVO (Callizo et al., 2019). 
(3) Gas Inhalation  
 Blockage of a retinal vein deprives an area of tissue of blood flow and the 
delivery of oxygen. Lower oxygen saturation in the occluded retinal vein was 
found to be associated with the level of ischemia in CRVO, but not BRVO 
(Šínová et al., 2018). Some studies have tried to examine the effect of hyperoxia 
on resolution of macular edema. The reasoning behind this is two-fold: first, 
oxygen causes vessels to constrict; second, oxygen will ameliorate tissue 
ischemia. Constriction of vessels may decrease leakage, while increased oxygen 
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saturation in the blood may prevent cell death. Oxygen was also found to 
downregulate the VEGF pathway in a mouse model of ischemic retinopathy, 
which may help improve macular edema (Liu et al., 2013).  
 Carbogen, a mixture of 95% oxygen and 5% carbon dioxide, has also 
been tested as an alternative to pure, 100% oxygen. Carbon dioxide may prevent 
oxygen-induced vasoconstriction and thereby allow for greater oxygen delivery to 
the retina. When carbogen inhalation was coupled with acetazolamide injection in 
a porcine model of ischemic retinopathy, it decreased ischemia due to acute 
BRVO (Pournaras et al., 2004). With more testing, hyperoxia may represent a 
possible noninvasive therapy for the reduction of ischemia and better visual 
outcomes in people with RVO. 
(4) Other Therapies 
 Since RVOs may be caused by thrombosis, some studies have examined 
the efficacy of systemic anticoagulant and antiplatelet therapies with drugs such 
as heparin, ticlopidine, and streptokinase (Arroyo, 2001; Kohner et al., 1976; 
Lazo-Langner et al., 2010). Researchers have also attempted surgical 
intervention and intravitreal injection of tissue plasminogen activator (tPA) on 
animal models and humans, respectively (Ameri et al., 2008; Chhablani et al., 
2010; Ghazi et al., 2003; Hattenbach et al., 2009; Lahey et al., 1999; Tameesh et 
al., 2004; Weizer & Fekrat, 2003).  
 Although in theory these therapies provide a way to address an important 
cause of RVO, the risks of hematological disorders with ticlopidine and vitreous 
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hemorrhage with streptokinase seem to outweigh the benefits of these drugs 
(Ageno et al., 2016). The relative dearth of clinical trials evaluating the efficacy of 
and optimal dosage schedules for heparin and tPA has likely hindered their 
implementation in the clinic (Shahid, 2006). 
 One proof-of-concept study in a rabbit model lays the foundation for a 
photochemical method of targeted drug delivery to a blood vessel in the retina 
(Arroyo et al., 1997). Although the aim of the study was to create a blood clot 
using a form of thrombin, their technique could theoretically be used to dissolve a 
blood clot with tPA. The researchers created a caged version of thrombin by 
covalently bonding a photosensitive inhibitor to a key active site serine. Exposing 
caged thrombin to violet light through the eyes released the inhibitor from the 
active site serine, regenerating active thrombin enzyme at the site of light 
exposure (Arroyo et al., 1997). Given that tPA is also a serine protease, it may be 
amenable to caging and photolysis in the same fashion as thrombin. At present, 
no studies have attempted to adapt this photoactivation approach to tPA (Lee et 
al., 2009). 
 Studies have also examined the benefits of combining injection with laser 
therapies (Chew, 2009; McAllister et al., 2018; Moon et al., 2016; Tadayoni et al., 
2017). Regardless of the treatment plan, patients with RVO should be kept under 
close observation. Recently, improvements on mass-spectrometry have enabled 
scientists to uncover changes in protein dynamics associated with RVO, which 
may lead to the development of new treatments. Proteomics have been 
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performed on retina, vitreous humor, and aqueous humor samples from humans 
and animals with RVO. In general, the proteins that change with RVO seem to be 
associated with cell-adhesion processes and extracellular matrix remodeling. 
Proteomic profiling may be a promising avenue for the development of innovative 
therapies for RVO (Cehofski et al., 2017). 
Outcomes and Prognosis for Retinal Vein Occlusions 
 The main outcomes of interest in RVO are best-corrected visual acuity 
(BCVA), macular edema, and neovascularization. While visual outcomes are 
usually moderate in both CRVO and BRVO, the average visual acuity tends to be 
lower in CRVO than in BRVO (McIntosh et al., 2010; Rogers et al., 2010). 
 According to one study, patients who present with a VA of 20/200 or 
worse due to CRVO were more likely to develop neovascularization and less 
likely to experience improved vision (The Central Vein Occlusion Study Group, 
1997). More specifically, ischemic CRVO is correlated with development of 
secondary neovascular glaucoma within 15 months while nonischemic CRVO is 
not (McIntosh et al., 2010). CRVO patients younger than 50 years old have better 
final VA than those aged 50 and older (Rothman et al., 2019). 
 In BRVO, outcome and prognosis for BCVA are worse with advanced age, 
greater central macular thickness, and a poor baseline VA. When the BRVO 
occurs where the vein crosses over the arteriole, the nonperfusion area was 
significantly higher and the crossing pattern may be associated with risk for 
neovascularization (Iida-Miwa et al., 2019). Intraretinal hemorrhage after acute 
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BRVO can exacerbate the treatment burden and worsen clinical outcomes 
(Powers et al., 2019).  
 Although some RVOs resolve spontaneously or after a small number of 
anti-VEGF injections, the majority of patients with RVOs require numerous 
injections to keep macular edema under control. One prospective case series 
examined outcomes for patients with CRVO and BRVO after 78 months and 58 
months, respectively. Within 6 months of follow-up, 75% of CRVO and 58% of 
BRVO patients required anti-VEGF injection. This suggests that more sustained 
anti-VEGF therapy is necessary to stabilize macular edema and improve 
outcomes (Iftikhar et al., 2019). With our current standard of care, RVO becomes 
a chronic disease for most patients. 
Differential Diagnoses 
 RVO should be distinguished from proliferative diabetic retinopathy and 
from ocular ischemic syndrome. All three diseases are associated with 
hemorrhage, macular edema, dilated retinal vessels, and neovascularization 
(Batterbury & Murphy, 2019; Yanoff & Sassani, 2014). If a patient does not have 
diabetes, it is more likely to be RVO. If a patient has diabetes, 
ophthalmodynamometry can help distinguish RVO from diabetic retinopathy 
(Robinson & Halpern, 1992). Measuring the transit time of dye when performing 
an FA can also elucidate the disease, since the flow of dye out of the eye or a 
region of the retina would be slower than expected in an RVO eye than in a PDR 
eye. Since ocular ischemic syndrome is caused by atherosclerosis of the carotid 
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artery, measuring the transit time of fluorescein dye is once again useful. In the 
case of ocular ischemic syndrome, the flow of dye from the time of injection in the 
area to the eye would be delayed (Mizener et al., 1997). 
 Other chief causes of sudden, painless monocular vision loss include 
anterior ischemic optic neuropathy, optic neuritis, papillophlebitis, and Terson’s 
syndrome. Retinal detachment and vitreous hemorrhage also cause sudden 
vision loss, though these may be secondary to RVO (Batterbury & Murphy, 2019; 
Yanoff & Sassani, 2014).  
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SPECIFIC AIMS 
 The goal of this exploratory, nonrandomized study was to quantitatively 
describe retinal vascular blood flow in patients with RVO and to create and 
explore a new measurement of RVO severity: relative blood flow (a unitless 
value). Blood flow data was collected using a fairly new technology called Laser 
Speckle Flowgraphy. The first objective was to characterize LSFG output in 
healthy eyes by establishing intra-patient consistency and stability of blood flow 
measurements over time. The second objective was to compare the blood flow in 
eyes with CRVO and BRVO with the blood flow in healthy eyes. The third 
objective was to identify any statistically significant correlations between 
demographic factors and RVO. This investigation will supplement current 
knowledge on retinal hemodynamics and may provide retina specialists and their 





 This study was an exploratory, preliminary analysis of retinal vascular 
blood flow in patients with retinal vein occlusions. 
Participants 
 We studied 20 control subjects with no ocular conditions or systemic 
diseases, and 32 patients diagnosed with unilateral retinal vein occlusion. 
Patients who presented to the clinic with sudden, painless vision loss in the entire 
visual field or in one quadrant of one eye were evaluated by a retina specialist. 
Diagnosis was primarily accomplished through a convergence of evidence from 
medical history, ophthalmoscopy, fluorescein angiogram (Optos California, 
Dunfermline, UK), and optical coherence tomography (Spectralis, Heidelberg 
Engineering, Heidelbergy, Germany). We identified 15 eyes with CRVO, and 17 
eyes with BRVO. 
 Patients who had any additional ocular disease in either eye, such as 
diabetic retinopathy or age-related macular degeneration, were excluded. 
Patients with dense cataracts were excluded from the study since cataracts 
interfere with data collection by LSFG. Patients with epiretinal membranes or 
secondary neovascular glaucoma associated with RVO were included in this 
study. 
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 The institutional review board at Beth Israel Deaconess Medical Center 
authorized this study, all patients provided informed consent, and research was 
conducted in accordance with the Declaration of Helsinki. 
Data Collection 
 A comprehensive ophthalmological exam was conducted on the patients 
at each clinic visit. A recent medical history was collected to document changes 
in visual acuity, including flashing lights and floaters, and any reports of ocular 
pain. Risk factors such as diabetes and hypertension, major systemic health 
conditions, and any other recent changes in health were noted. Current 
medications and eye drops were confirmed. 
 The patients’ visual acuity was evaluated using a Snellen or an Early 
Treatment Diabetic Retinopathy Study (ETDRS) chart and a handheld occluder. 
Patients performed the visual exam wearing distance glasses or bifocals, if 
applicable, and an occluder. In some cases, the pinhole attachment on the 
occluder was used to obtain the best corrected visual acuity (BCVA). All BCVA 
values were converted in the Logarithm of Minimum Angle of Resolution 




















20/16  -0.10 20/100 +0.70 
20/20   0.00 20/125 +0.80 
20/25 +0.10 20/160 +0.90 
20/32 +0.20 20/200 +1.00 
20/40 +0.30 20/250 +1.10 
20/50 +0.40 20/320 +1.20 
20/63 +0.50 20/400 +1.30 
20/80 +0.60 CF 2 feet* +2.00 
LogMAR = -Log(20 / distance in feet of best line read) 
*CF 2 feet = eye can count fingers at a distance of 2 feet 
 
 IOP was measured in millimeters of mercury (mmHg) using a Tonopen 
(Reichert Inc., Buffalo, NY, USA) after applying topical anesthetic to each eye 
(proparacaine hydrochloride 0.5%). Eyes were not dilated unless required for 
subsequent blood flow measurements.  
 As a supplement to fundoscopy, various ocular imaging techniques were 
used to diagnose RVO and monitor the macula for complications. Upon first 
encounter, a wide-field fluorescein angiogram was acquired to identify the area of 
venous occlusion. At each visit, three types of OCT scans of the macula were 
taken: two line-scans at 0 and 90 degrees, and a fast-scan for a 25-scan 
composite image of the macula. The CMT measurements were obtained from the 
foveolar area of the fast scan output. 
 We used LSFG-NAVI to measure the dynamics of retinal circulation. This 
imaging technology (Softcare Co., Ltd., Fukuoka, Japan) has been used in 
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numerous studies as a robust method of measuring and quantifying ocular blood 
flow (Iwase et al., 2015; Luft et al., 2016a; Shiga et al., 2014, 2015; Sugiyama et 
al., 2010). The system is comprised of a laser and fundus camera. Erythrocytes 
traveling through retinal vessels scatter the laser, and the constructive and 
destructive interference creates a laser speckle pattern that is captured by a 
CCD camera.  
 Softcare Co., Ltd. has devised a terminology to describe the output of 
LSFG (Figure 9). Over the course of about four seconds, the LSFG software 
generates “heartbeat maps” for each frame based on the laser speckle pattern. 
These heartbeat maps are then overlaid on one another to form a “composite 
map.” Markers called rubber bands allow for targeted analysis of various regions 
such as the macula or individual blood vessels. The elliptical rubber band, which 
is partitioned into four quadrants (superior, temporal, inferior, and nasal) can be 
used to analyze the optic nerve head (ONH) area. The light intensity map allows 
for accurate, manual placement of the elliptical rubber band onto the heartbeat 
map. The software can then analyze the area within the rubber band to generate 
quantitative data. 
 Mean blur rate (MBR) is a numerical measure of the blood flow within the 
rubber band area. MBR is calculated by comparing the mean velocity of all cells 
in the measurement area (the static cells of the tissue and the erythrocytes 
moving through vessels) with the mean velocity of the dynamic cells (the 
erythrocytes) in the measurement area. MBR is therefore a unitless value that 
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represents relative blood flow velocity in an area and can vary based on tissue 
characteristics. In particular, increasing retinal pigmentation leads to decreasing 
MBR values, so laser intensity must be adjusted using the Pigmagic software to 
account for differences between subjects. 
 Using the elliptical rubber band and the composite map, we can obtain 
various MBR-based readouts of relative blood flow in the four quadrants of the 
ONH area. The primary values of interest to us in this study are MV, MT, MA, 
and MV-MT (Table 1). MT is a measure of the movement of erythrocytes within 
the choriocapillaris. MV-MT isolates the relative blood flow within the retinal 
vessels by excluding the mean blur rate of the underlying choroidal tissue. 
Table 3. Definition of blood flow measures using mean blur rate (MBR) 
obtained from a composite map 
MV mean MBR of vascular area (higher MBR area) within the rubber band 
MT mean MBR of tissue area (lower MBR area) within the rubber band 
MA mean MBR of the entire area within rubber band, usually equivalent to average 
MV – MT  the difference of the mean vascular MBR and the mean tissue MBR within the rubber band 
 
 For all subjects of this study, we performed LSFG in both eyes. Patients 
were dilated only if necessary with 1% tropicamide, which does not affect retinal 
blood flow (Luft et al., 2016b). We have two sets of controls. First, we used 
control subjects’ eyes, which have no previous history of ocular disease or 
procedures, no diabetes, no hypertension, and are otherwise healthy. These 
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were primarily used to determine the inter- and intra-patient MBR correlation and 
to establish the feasibility of using patients’ healthy fellow eye as an expected 
value. Second, we used patients’ healthy fellow eye, having been established as 
a satisfactory expectation. This will be our primary point of comparison for 
analytical purposes to mitigate the effects of the observed inter-patient variability. 
 We will now introduce our own terminology, which more specifically 
describes the data we collected and analyzed from LSFG (Figure 9). We replace 
the term heartbeat map with “frame MBR” to reflect the instantaneous MBR 
values we obtain with each frame via an elliptical rubber band on the ONH area. 
We used MV-MT values to isolate the blood flow in the retinal vessels, and from 
now on, any reference to MBR values will imply the MV-MT values. When 
heartbeat maps are combined to form a composite map, these MBR values form 
a graphical representation of a heartbeat cycle. For ease of analysis, we average 
the frame MBRs over a single heartbeat cycle to get a “heartbeat MBR,” 
disregarding frame-by-frame variation. For both eyes of each patient, we 
acquired three heartbeat MBRs from three different heartbeat cycles to minimize 
any variation that may be due to differences in blood flow between a patient’s 
heartbeats. We average three heartbeat MBR values to get an “average single 
eye MBR” with standard deviation. Finally, we divide a patient’s average single 
eye MBR from their RVO eye by the average single eye MBR in their healthy 
fellow eye to get a “relative blood flow.” We use relative blood flow (RBF) as our 
primary metric of blood flow. Since LSFG represents a way to quantify retinal 
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blood flow, we believe it will provide a deeper understanding of blood flow 
changes in patients with retinal vein occlusions and optimize treatment 
schedules. 
Demographics Variables and Disease Characteristics 
 Through medical chart review, we identified whether patients had received 
surgery or laser treatment on either eye prior to the blood flow measurement. 
Duration of RVO is the amount of time between first diagnosis and measurement 
of blood flow. Total number of injections takes into account all injections the 
patient has received for RVO, both before and after the measurement (Table 7). 
We examined BCVA for 31 patients at the time of blood flow measurement, 
month zero, and repeated measurements one month and three months later.  
Statistical Analyses 
 The primary analysis consisted of a Welch’s t-test between the relative 
blood flow of CRVO and BRVO eyes to healthy controls. The relative blood flow 
of healthy controls considered patients’ left eye to be the “diseased” eye and 
numerator of the RBF ratio. We then performed a series of univariate analyses 
between demographic variables and disease characteristics. These analyses 
consisted of either Welch t-tests or Pearson’s Correlation Coefficients, depending 
on the nature of the grouping variable. All descriptive statistics and graphs in the 
Appendix were created using SPSS (IBM Co., Armonk, New York, USA).  
Calculations of RBF and all related analyses and graphs were generated using R 





Figure 9. LSFG output, data analysis workflow, and terminology. Each 
heartbeat cycle, measured over the course of a few seconds, generates a finite 
number of heartbeat maps (usually around 20-30). Here we have depicted five 
frames per heartbeat cycle, with the corresponding heartbeat maps below the x-
axis. These heartbeat maps are combined to form one composite map for one 
heartbeat cycle. Although the manufacturers of LSFG, Softcare Co, have devised 
a terminology for LSFG outputs, we have formulated our own terminology to 
clarify our data analysis. We imaged three heartbeat cycles per eye per patient, 
generating a total of six composite maps per visit. The heartbeat MBR values are 
the average MBRs of each heartbeat cycle. The three heartbeat MBRs for each 
eye are averaged to give two average single eye MBRs. The average single eye 
MBR for the RVO eye of a patient is divided by the average single eye MBR of 
the healthy, fellow eye of the same patient to give the relative blood flow. 
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RESULTS 
Blood Flow in Healthy Eyes 
 In order to characterize the expected retinal blood flow in the optic nerve 
head area of healthy eyes, we obtained the LSFG output of the eyes of 20 
control patients with no ocular conditions. Figure 10 is a graphical representation 
of all frame MBR values collected from one subject with no ocular conditions at 
two imaging sessions, and Figure 11 displays data from all 20 healthy subjects. 
For ease of analyses, we will compare the average MBR values over the course 
of a heartbeat in the upcoming sections (heartbeat MBR). 
 We found no statistically significant difference between the eyes of each 
control subject (F1 = 0.83, P = .37). We also found no statistically significant 
difference between repeat imaging sessions of each control subject (F1 = 0.012, 
P = .91). We found statistically significant differences when we compared the 
heartbeat MBR values obtained from the healthy eyes of multiple control subjects 
(F19 = 14.60, P < .001) (Figure 11). Thus, the heartbeat MBR measurement is 




Figure 10. Frame mean blur rate measurements of the healthy eyes of one 
control subject with no ocular conditions at two separate sessions. Aqua 
dots represent frame MBR values collected from the ONH are of the right eye 
(R). Red dots represent frame MBR values collected from the ONH area of the 
left eye (L). The imaging sessions occurred on two dates: 11 July 2019 (left 
panel) and 06 August 2019 (right panel). Time is measured in seconds (s) and 
MBR in arbitrary units. At each imaging session, three composite maps were 
collected. Images for the composite map were taken automatically over a 
heartbeat cycle, which is reflected in the MBR values and shape of the graphs. 
There are no significant differences between the left and right eyes of this patient 
(F1 = 0.83, P = 0.37). Additionally, there are no significant differences between 
measurements collected at the two sessions (F1 = 0.013, P = .91). 
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Figure 11. Frame mean blur rate measurements of the healthy eyes of all 
control subjects (n = 20). Each color represents a different patient. Time is 
measured in seconds (s) and MBR in arbitrary units. The overall shape of the 
graph represents the heartbeat cycles of multiple subjects. There is a statistically 
significant difference in heartbeat MBR values between patients (F19 = 14.60, P 
< .001). 
Patient’s Healthy Fellow Eye as an Expectation  
 The goal of analyzing healthy control patients was to determine if patients 
with monocular diseases could use the blood flow in their healthy, fellow eye as 
an expectation for blood flow in their diseased eye. Specifically, we wanted to 
know if the mean blur rate of a patient’s healthy, fellow eye could serve as an 
expected value for their diseased eye. If their healthy, fellow eye has a fairly 
consistent mean blur rate, then we can divide the average single eye MBR of 
their diseased eye by the average single eye MBR of their healthy eye to get a 
relative blood flow measurement. The importance of the relative blood flow 
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measurement is that it quantifies, as a percentage, the extent to which their 
disease has affected the retinal vascular blood flow in that eye.  
 Figure 12 shows the distribution of the differences in heartbeat MBR 
between the two eyes of each control subject. It is a nearly normal distribution 
with 95% of patients’ eyes differing by 7 units or less. One way to measure the 
potential error in using patients’ fellow eyes as reference is to calculate the root-
mean-squared-error (RMSE) of a linear regression model predicting a patient’s 
right eye MBR from their left eye’s value. RMSE is particularly useful as it is a 
measurement of the average difference between values that gives greater weight 
to larger deviations. We wanted to avoid the possibility of large discrepancies 
producing false relative blood flow measurements and skewed results. The 
RMSE of a linear regression model predicting right eye MBR using the same 
patient’s left eye MBR and an intercept of 0 is 2.79, a difference of 13.8% from 




Figure 12. Difference in heartbeat mean blur rate between the eyes of all 
control subjects (n = 20). The goal of this initial analysis was to determine if 
patients’ healthy, fellow eyes could be used as healthy expectations for their 
diseased eyes. If so, their relative blood flow (MBR of disease eye divided by 
their MBR of healthy eye) would be a useful metric that describes the effect of 
their disease on retinal vascular blood flow. The first step in this process was to 
explore the difference in heartbeat MBR between the eyes of control subjects. 
For each control subject, heartbeat MBR values from the right eye were 
subtracted by the heartbeat MBR values from the left eye and plotted. 95% of 
patients had MBR within 7 units of their other eye, with an RMSE 2.79. 
 
Blood Flow in Eyes with Retinal Vein Occlusions 
 The average single eye MBR of the CRVO eye of patients was lower than 
that of their healthy, fellow eye. We found that, on average, the blood flow of a 
CRVO eye was 74±5% that of the blood flow of the healthy eye, indicating a 26% 
average reduction in blood flow due to the occlusion (Figure 13). The average 
single eye MBR of the BRVO eye of patients was also lower than that of their 
healthy, fellow eye. We found that, on average, the blood flow of a BRVO eye 
was 93±5% that of the blood flow of the healthy eye, indicating a 7% average 
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reduction in blood flow due to the occlusion (Figure 13). To incorporate the 
terminology that we defined earlier, the relative blood flow of CRVO eyes was 




Figure 13. Average relative blood flow in healthy eyes and eyes with central 
and branch retinal vein occlusion. The red box plot shows the average relative 
blood flow of eyes with CRVO (n = 15, mean ± SD = 0.74 ± .05, P < .001). The 
green box plot shows the average relative blood flow of eyes with BRVO (n = 17, 
mean ± SD = 0.93 ± .05, P = .15). The blue box plot shows the average relative 
blood flow of healthy eyes (n = 32, mean ± SD = 1 ± .01). The average relative 
blood flow of healthy eyes took the patient’s left eye as the “diseased” eye during 
calculations.   
Demographics of Retinal Vein Occlusions 
 We examined the association of a variety of demographic factors, 
systemic and ocular conditions, treatments, and visual acuity (Tables 4-6) with 
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the relative blood flow. The average age of patients was 67.53 years, the median 
age was 69.5 years, the standard deviation (SD) was 12.3 years, the minimum 
was 33 years, and the maximum was 93 years of age (Appendix, Figure A).  
 For the duration of RVO data set, even though an outlier at 240 months 
was excluded, the data is left skewed. Likewise, the data set for total number of 
injections has left skew. For these two variables, median is a better metric for 
analysis (Appendix, Figures B-C). The statistics of these two variables are 
summarized in Table 7. 
 BCVA was recorded for 31 patients at the time of blood flow measurement 
(month zero), for 11 patients one month after the blood flow measurement, and 9 
patients three months after the blood flow measurement (Table 8). BCVA at 
month zero, one, and three are shown in Table 9 and in boxplot form, stratified 
by need for injection within 3 months after blood flow measurement (Appendix, 
Figure D). BCVA was recorded at all three time points for only five patients 
(Appendix, Figure E). Only one of those patients, signified by the orange line, 
received an injection within three months after blood flow measurement. There 
was no correlation between RBF and BCVA at month zero in either CRVO eyes 
(r = -0.03, P = .84) or BRVO eyes (-0.29, P = .14) eyes. 
 In CRVO patients, we found no significant association between RBF and 
phakic status, cataract, glaucoma, high cholesterol, hypertension, and total 
number of injections. We found there was a significant association between RBF 
and diabetes (t19 = -3.44, P = .0028), previous laser (t23 = -3.30, P = .0032), 
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previous injection (t27 = -2.96, P = .0064), need for an injection within three 
months after blood flow measurement (t33 = 2.61, P = .013), the duration of 
CRVO (t39 = 4.56 , P < .001), CMT (t40 = 3.12, P = .0034), and IOP (t40 = -2.27, P 
= .029). In BRVO patients, we found no significant association between RBF and 
any demographic variable. All P-values for RBF and RVO are summarized in 
Table 10.  
 Table 11 lists the RBFs of patients with or without the dichotomous 
demographic factors significantly correlated with CRVO. Patients with diabetes, 
previous laser, or previous injection displayed increased RBFs at the time of 
measurement in relation to those who did not (Table 11). Patients who needed 
an injection within three months after the time of measurement had decreased 
RBF at the time of measurement in relation to those who did not need an 
injection (Table 11). 
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Table 4. Frequencies and percentages of dichotomous and categorical 
demographic characteristics 
Characteristic Frequency Percent Characteristic Frequency Percent 
Eye     Phakic Status     
Left 32 50 PCIOL 19 29.7 
Right 32 50 Phakic 45 70.3 
Total 64 100 Total 64 100 
Sex     Cataract     
Female 18 56.3 Yes 26 59.4 
Male 14 43.8 No 38 40.6 
Total 32 100 Total 64 100 
Hypertension     Glaucoma     
Yes 40 62.5 Yes 8 12.5 
No 24 37.5 No 56 87.5 
Total 64 100 Total 64 100 
Diabetes     High Cholesterol     
Yes 20 31.3 Yes 26 40.6 
No 44 68.8 No 20 31.3 
Total 64 100 Not specified 18 28.1 
    Total 64 100 
Race     Hispanic     
Asian 3 9.4 Yes 5 16.1 
African American 8 25.0 No 26 83.9 
Hispanic 4 12.5 Not specified 1 -- 
White 15 46.9 Total 32 100 
Not specified 2 6.3      
Total 32 100      
Disease     BRVO Type     
BRVO 14 43.8 Inferior 5 29.4 
BRVO; ERM 2 6.3 Superior 8 47.1 
BRVO; NVD* 1 3.1 Not specified 4 23.5 
BRVO Total 17 53.1 Total 17 100 
CRVO 13 40.6 
  
  
CRVO; ERM 2 6.3   
 
  
CRVO Total 15 46.9  
Total 32 100  *NVD = neovascularization of optic disk 
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Table 5. Frequencies and percentages of treatments received before blood 
flow measurement  
  Frequency Percent   Frequency Percent 
Surgery prior to blood flow Laser prior to blood flow 
BRVO     BRVO     
Yes 8 47.1 Yes 16 94.1 
No 9 52.9 No 1 5.9 
Total 17 100 Total 17 100 
CRVO     CRVO     
Yes 3 20 Yes 12 80 
No 12 80 No 3 20 
Total 15 100 Total 15 100 
Disease Eye     Disease Eye     
Yes 11 34.4 Yes 28 87.5 
No 21 65.6 No 4 12.5 
Total 32 100 Total 32 100.0 
Fellow Eye     Fellow Eye     
Yes 7 21.9 Yes 1 3.1 
No 25 78.1 No 31 96.9 
Total 32 100 Total 32 100.0 
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Table 6. Frequencies and percentages of injection before and after blood 
flow measurement 
Injection prior to blood flow Injection within 3 months  after blood flow 
BRVO     BRVO     
Yes 14 82.4 Yes 5 29.4 
No 3 17.6 No 9 52.9 
Total 17 100 Not specified 3 17.6 
   Total 17 100 
CRVO     CRVO     
Yes 11 73.3 Yes 6 40.0 
No 4 26.7 No 6 40.0 
Total 15 100 Not specified 3 20.0 
   Total 15 100 
Disease Eye     Disease Eye     
Yes 25 78.1 Yes 11 34.4 
No 7 21.9 No 15 46.9 
Total 32 100.0 Not specified 6 18.8 
     Total 32 100.0 
 
Table 7. Statistics on the duration of retinal vein occlusion and total 
number of injections received 
  n Mean Median SD Range Min Max 
Duration of RVO in months 
(in years) 









Total Number of Injections 32 6.69 5 6.20 20 0 20 
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Month 3  
(LogMAR) 
BRVO n Valid 17 6 7 
    Missing 0 11 10 
  Mean  0.40 0.27 0.50 
  Median   0.30 0.24 0.48 
  SD   0.29 0.11 0.30 
  Range   1.24 0.27 0.86 
  Minimum   0.06 0.13 0.14 
  Maximum   1.30 0.40 1.00 
CRVO n Valid 14 5 2 
    Missing 1 10 13 
  Mean  0.30 0.12 0.17 
  Median   0.30 0.13 0.17 
  SD   0.29 0.15 0.09 
  Range   1.15 0.43 0.13 
  Minimum   0.00 -0.10 0.10 
  Maximum   1.15 0.33 0.23 
*BCVA Month 0 is the best corrected visual acuity of patients at the  




Table 9. BCVA values of RVO patients 0, 1, and 3 months after blood flow 
measurement stratified by need for injection within 3 months after blood 
flow measurement 
Need for Injection Within 
3 Months After Blood 
Flow Measurement 
BCVA  






Month 3  
(LogMAR) 
No n Valid 14 8 4 
    Missing 26 32 36 
  Mean   0.29 0.20 0.24 
  Median   0.30 0.21 0.19 
  SD   0.16 0.16 0.17 
  Range   0.53 0.50 0.38 
  Minimum   0.00 -0.10 0.10 
  Maximum   0.53 0.40 0.48 
Yes  n Valid 11 2 4 
    Missing 0 9 7 
  Mean   0.49 0.23 0.65 
  Median   0.35 0.23 0.65 
  SD   0.42 0.14 0.29 
  Range   1.28 0.20 0.70 
  Minimum   0.02 0.13 0.30 
  Maximum   1.30 0.33 1.00 
NA n Valid 6 1 1 
    Missing 7 12 12 
  Mean   0.26 0.08 0.27 
  Median   0.25 0.08 0.27 
  SD   0.15 -- -- 
  Range   0.40 0.00 0.00 
  Minimum   0.10 0.08 0.27 
  Maximum   0.50 0.08 0.27 
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Table 10. Test statistics, correlations, and P values comparing relative 
blood flow and demographic variables in retinal vein occlusions 
 CRVO BRVO 
 t statistic df P value t statistic df P value 
Phakic Status 1.28 10 0.23 0.219 24 0.83 
Cataract -1.52 13 0.15 -0.37 22 0.72 
Glaucoma 1.56 5 0.18 1.39 7 0.21 
High Cholesterol 0.41 22 0.69 0.57 14 0.58 
Hypertension -0.71 38 0.48 -0.47 8 0.65 
Diabetes -3.44 19 0.0028 -0.96 20 0.35 
Previous Laser -3.30 23 0.0032 0.96 3 0.42 
Previous Injection -2.96 27 0.0064 0.34 9 0.74 
Injection within 3 months after 
blood flow measurement 2.61 33 0.013 0.56 14 0.58 
 correlation 
coefficient P value 
correlation 
coefficient P value 
RVO Duration 0.59 <0.001 0.17 0.40 
CMT (Month 0) 0.44 0.0034 -0.28 0.15 
IOP (Month 0) -0.34 0.029 -0.26 0.29 
BCVA (Month 0) -0.03 0.84 -0.29 0.14 
Total Injection 0.20 0.21 -0.19 0.33 
Statistically significant values, with a P < 0.05 have been bolded. 
 
Table 11. Average relative blood flow for statistically significant 
dichotomous demographic variables 
Average Relative Blood Flow* in CRVO 
 Yes No 
Diabetes 0.82 0.60 
Previous Laser 0.70 0.52 
Previous Injection 0.70 0.53 
Need for injection within 3 months of 
blood flow measurement 0.59 0.76 
*Relative blood flow = average single eye MBR of 
CRVO eye / average single eye MBR of healthy, fellow eye.  
In this chart, we averaged the relative blood flows for  
patients with CRVO (n = 15). Numbers closer to 1 indicate  




 In this study, we used LSFG to quantify and compare the blood flow in the 
eyes between and within control subjects. We used this data to validate the blood 
flow in patients’ healthy eyes as an expectation for the blood flow in their RVO 
eye. We created a metric called relative blood flow to compare the blood flow in 
diseased eyes to healthy eyes. Finally, we identified the demographic factors that 
were significantly associated with differences in relative blood flow. 
 We found that blood flow (average single eye MBR) in each eye of the 
same control subject were not different, but that the blood flow in the eyes of 
different control subjects varied significantly. In patients with unilateral RVO, this 
finding allowed us to use the blood flow of their healthy, fellow eye as a healthy 
expectation for blood flow in their diseased eye. This allowed us to create a novel 
metric: relative blood flow, which is the blood flow in the RVO eye divided by the 
blood flow in the healthy eye. Relative blood flow is a descriptor of the extent to 
which a retinal vein occlusion impedes blood flow--the severity of an RVO. 
 We found a 25% average reduction in the relative blood flow of CRVO 
eyes, and a 7% average reduction in the relative blood flow of BRVO eyes. Since 
central retinal vein occlusions occur in larger veins than branch retinal vein 
occlusions, it makes sense that we would see a greater reduction in blood flow in 
CRVO eyes. 
 When we looked at the effects of dichotomous demographical variables on 
relative blood flow in CRVO eyes, patients with diabetes had significantly higher 
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relative blood flow on average than those without. The precise mechanism of this 
unclear. It is possible that our sample size was too small, the patients with 
diabetes were controlling it well, or that the diabetic patients had little macular 
edema. A recent meta-analysis showed that diabetes is not a significant risk 
factor for RVO (Song et al., 2019). More research must be done to elucidate why 
patients with diabetes had less severe CRVO.  
 Having laser treatment or injection prior to blood flow measurement were 
also significantly associated with greater relative blood flow. Laser 
photocoagulation and anti-VEGF injections both work to prevent 
neovascularization. This suggests that decreasing VEGF levels leads to 
improvement in blood flow. A more detailed follow-up study, taking into account 
the number and timing of previous laser and injection treatments, may further 
elucidate the details of this finding. 
 There was a significant association between relative blood flow and need 
for an injection within three months after blood flow measurement in patients with 
CRVO. CRVO eyes with, on average, a 41% reduction in blood flow (59% 
relative blood flow) did need an injection. CRVO eyes with, on average, a 24% 
reduction in blood flow (76% relative blood flow) did not need injection. This 
indicates patients with severe CRVOs, ones resulting in lower relative blood flow, 
are more likely to receive an injection within three months. Therefore, LSFG may 
assist clinicians in assessing risk of additional injection in their patients with 
CRVO. 
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In CRVO, we found that relative blood flow was significantly positively 
correlated with the duration of the occlusion, suggesting that the retinal blood 
flow in the occluded eye recovers over time. Interestingly, in BRVO, this was not 
the case. Blood flow did not recover significantly over time, but the average 
reduction is only 7% so the size of the effect may be too small to detect with our 
current sample size. It is also possible that restoration of blood flow is 
accomplished in a unique way following CRVO.  
 There was also a positive correlation between relative blood flow and 
CMT, suggesting that greater blood flow in CRVO eyes may contribute to 
increased macular edema. We found a negative correlation between relative 
blood flow and IOP, perhaps because high IOP may cause venous compression 
and thereby additionally inhibit blood flow.  
 We did not uncover any significant associations or correlations with 
relative blood flow and BRVO. This may be because the reduction in blood flow 
is so small that detecting significant changes with our sample size is not possible. 
The location of a BRVO may also play a larger role in impeding blood flow, which 
may not have been captured by our LSFG analysis methods.  
Limitations 
 This study has several limitations. First, the sample size was relatively 
small and may be ungeneralizable and underpowered to detect small differences. 
This was caused primarily by our small recruitment base (patients in BIDMC’s 
Eye Clinic), but was exacerbated by the labor-intensive data collection, which 
 56 
may be an issue for this device’s practical utility. Second, like all imaging 
devices, LSFG was less effective on patients with media opacities or who had 
difficulty fixating their vision. Third, we only collected and analyzed blood flow 
data from the entire ONH area of the retina. Changes to relative blood flow in 
certain quadrants of the ONH area, or other regions of the retina, were not 
examined. Finally, the limited timeframe of this study impeded our ability to 




 In this exploratory study, we were able to validate LSFG as a reliable 
technology for the measure of intra-patient retinal blood flow and created a new 
metric of retinal vein occlusion severity, relative blood flow. We used this 
measure to quantify the decreased blood flow in eyes with retinal vein occlusion. 
We found significant associations between relative blood flow in CRVO and 
diabetes, previous laser, previous injection, need for injection within three months 
of blood flow measurement, duration of occlusion, central macular thickness, and 
intraocular pressure. Future studies can be done to elucidate these findings—in 
particular, to assess if relative blood flow can be used as a predictive factor for 
whether or not a patient will need an injection in the next three months. As a 
severity metric for retinal vein occlusion, relative blood flow may add depth to 






Figure A. A histogram of age (in years). The data follows a fairly normal 
distribution. Most patients with RVO around 70 years of age. 
 
 
Figure B. A histogram of RVO duration. Note that an outlier at 240 months 




Figure C. A histogram of total number of injections. The data is left skewed, 
with eight patients receiving no injection. 
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Figure D. Boxplots of best 
corrected visual acuity at 
month 0, 1, and 3 stratified by 
need for injection within 3 




LogMAR_BCVA_M3 on the y-
axes, are the BCVAs converted 
to LogMAR units for Month 0, 
Month 1, and Month 3, 
respectively. Smaller numbers 
correspond to better vision, see 
Table 2 for information. 
Injection_M3, on the x-axes, is 
the need for injection within 3 
months after blood flow 
measurement. If no, value = 0. 
If yes, value = 1. If data was not 
available, value = NA. Top 
panel: data from Month 0, n = 
31. One patient was excluded 
from data set. Middle panel: 
data from Month 1, n = 11. 
Bottom panel: data from Month 



















Figure E. Change in visual acuity of five patients over 3 months following 
blood flow measurement. The visual acuities of five patients were recorded 
over the course of one and three months following the visit at which their retinal 
blood flow was measured. The scale is in LogMAR units, where smaller numbers 
correspond to better vision. Only the patient represented as an orange line 
received an injection within 3 months after the blood flow measurement. It is 
worth noting that this patient is also one of two patients who has received the 
maximum number of total injections (20) within our patient sample group. 
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